title: [Quality of life in the course of enzyme replacement therapy for chronic pancreatitis].
abstract: OBJECTIVE
  The ultimate goal of any treatment in chronic pancreatitis is to maximize the patient's quality of life. The authors evaluated the QoL of patients with chronic pancreatitis prior to and after pancreatic enzyme replacement therapy in a prospective, multicenter, follow-up study.
  
  
  METHODS
  Two groups of patients were evaluated. Group 1: 31 patients with newly diagnosed chronic pancreatitis who had never been treated with pancreatic enzyme preparations; Group 2: 39 patients whose disease was diagnosed on average 3.4 years before the start of the study. The latter group of patients had undergone pancreatic enzyme replacement therapy, but during the follow-up this proved to be insufficient. The dose of pancreatic enzyme replacement therapy was tailored in accordance with the degree of pancreatic exocrine insufficiency measured by means of exocrine pancreatic function tests.
  
  
  RESULTS
  A significant gain in body weight and a significantly reduced defecation rate were found in both groups 1 month after the beginning of the pancreatic enzyme replacement therapy as compared to the pretreatment values. The prevalence of general and disease-specific symptoms, and the intensity of pain were reduced in both groups after 1 month of enzyme substitution therapy. The working ability, the emotional functioning, the financial strain and the overall QoL score were improved significantly in both groups, while the cognitive functioning was found to be significantly improved during the follow-up only in Group 1. The overall increase in the QoL score correlated significantly with the increase in body weight and the decrease in defecation number in both groups.
  
  
  CONCLUSIONS
  Individually-tailored enzyme replacement therapy improved the QoL, reduced the extents of steatorrhea and pain, increased the body weight, not only in the untreated chronic pancreatitis patients, but even in the inadequately treated group.
authors.affiliation: Szegedi Tudományegyetem, Altalanos Orvostudományi Kar, Szent-György Albert Orvos- és Gyógyszeresztudományi Centrum, I. Belgyógyászati Klinika, Szeged.
authors.forename: László
authors.initials: L
authors.lastname: Czakó
authors.forename: Tamás
authors.initials: T
authors.lastname: Takács
authors.forename: János
authors.initials: J
authors.lastname: Lonovics
authors.forename: Lilla
authors.initials: L
authors.lastname: Lakner
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Döbrönte
authors.forename: László
authors.initials: L
authors.lastname: Prónai
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Tulassay
mesh_terms: D000328:Adult; D000368:Aged; D000681:Amylases / Q000008:administration & dosage*; D002908:Chronic Disease; D010450:Endopeptidases / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008049:Lipase / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology*; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008049:Lipase; D000681:Amylases; D010450:Endopeptidases